A 0.5-mg/kg dose of a low molecular weight heparin, enoxaparin, resulted in less non-coronary-artery bypass grafting (CABG) bleeding compared with unfractionated heparin in the first 48 hours after elective percutaneous coronary intervention (PCI), according to a prospective, open-label, multicenter, randomized trial reported in the New England Journal of Medicine.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Less CABG bleeding observed with enoxaparin compared with unfractionated heparin after PCI

Newsletter